# US 9,750,741 B2 · Targeted therapies for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,750,741 B2
- Document ID: US9750741B2
- Status: Granted
- Kind: B2
- Application number: 14/776,552
- Filed: 2014-03-17
- Published: 2016-02-11
- Granted: 2017-09-05
- Earliest claimed: 2013-03-15
- Assignees: The Translational Genomics Research Institute; Mayo Foundation for Medical Education and Research
- Applicants: The Translational Genomics Research Institute; Mayo Foundation for Medical Education and Research
- Inventors: Mitesh Jivraj Borad; David Craig; John Carpten
- Web page: https://patentgrep.com/patent/US9750741B2

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods of selecting a chemotherapy regimen for treatment of cancer in a patient are disclosed. A patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFI1 and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFI1 is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer.

## Claims

### Claim 1

A method of treating biliary tract cancer, comprising the steps of: analyzing a patient tumor sample for a mutation in ERRFI1 wherein said mutation in ERRFI1 comprises E384X; and treating said patient with an inhibitor of Epidermal Growth Factor Receptor (EGFR) if said mutation is present.

### Claim 2 (depends on 1)

The method of claim 1, wherein said biliary tract cancer is a cholangiocarcinoma.

### Claim 3 (depends on 2)

The method of claim 2, wherein said EGFR inhibitor is selected from the group containing erlotinib and gefitinib.

### Claim 4 (depends on 1)

The method of claim 1, wherein said EGFR inhibitor is selected from the group containing erlotinib and gefitinib.

### Claim 5 (depends on 1)

The method of claim 1, wherein said analyzing step comprises subjecting the patient tumor sample to amplification and exome sequencing.

### Claim 6 (depends on 1)

The method of claim 1, further including assessing effects on said cancer through tomography following a course of treatment.

### Claim 7

A method of inhibiting biliary tract cancer cell growth, comprising contacting a biliary tract cancer cell containing a mutation in ERRFI1 with an Epidermal Growth Factor Receptor (EGFR) inhibitor, wherein said mutation in ERRFI1 comprises E384X.

### Claim 8 (depends on 7)

The method of claim 7, wherein said biliary tract cancer is a cholangiocarcinoma.

### Claim 9 (depends on 7)

The method of claim 7, wherein said EGFR inhibitor is selected from the group containing erlotinib and gefitinib.

### Claim 10 (depends on 7)

The method of claim 7, wherein said inhibitor is erlotinib at a dosage of about 150 mg orally per day.

### Claim 11 (depends on 7)

The method of claim 7, wherein said mutation in ERRFI1 is confirmed through exome sequencing.

### Claim 12 (depends on 7)

The method of claim 7, further including assessing growth inhibition through tomography following a course of treatment.